A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome

被引：23
作者：
Gardner, Jennifer M. [1 ]
Introcaso, Camille E. [1 ]
Nasta, Sunita D. [2 ]
Kim, Ellen J. [1 ]
Vittorio, Carmela C. [1 ]
Rook, Alain H. [1 ]
机构：
[1] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2009年 / 61卷 / 01期
关键词：
THERAPY; BEXAROTENE; INHIBITORS; TRIAL; CELLS;
D O I：
10.1016/j.jaad.2008.11.889
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Long-term prognosis for advanced stages of cutaneous T-cell lymphoma may be beneficially altered with the use of multimodality therapy. However, refractory disease exists in Which current therapeutic options fail to halt the progression of disease. We present 3 cases of refractory Sezary syndrome in which the combination of vorinostat and interferon gamma was well tolerated and produced significant clinical improvement. The potential immunologic basis for this is discussed. (J Am Acad Dermatol 2009;61:112-6.)
引用
收藏
页码：112 / 116
页数：5
相关论文
共 14 条
[1]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[2]   Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma [J].
Duvic, Madeleine ;
Vu, Jenny .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) :1111-1120
[3]   Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].
Duvic, Madeleine ;
Talpur, Rakshandra ;
Ni, Xiao ;
Zhang, Chunlei ;
Hazarika, Parul ;
Kelly, Cecilia ;
Chiao, Judy H. ;
Reilly, John F. ;
Ricker, Justin L. ;
Richon, Victoria M. ;
Frankel, Stanley R. .
BLOOD, 2007, 109 (01) :31-39
[4]   Medical progress - The pathogenesis of mycosis fungoides [J].
Girardi, M ;
Heald, PW ;
Wilson, LD .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (19) :1978-1988
[5]   HDAC inhibitors: Clinical update and mechanism-based potential [J].
Glaser, Keith B. .
BIOCHEMICAL PHARMACOLOGY, 2007, 74 (05) :659-671
[6]   Immunopathogenesis and therapy of cutaneous T cell lymphoma [J].
Kim, EJ ;
Hess, S ;
Richardson, SK ;
Newton, S ;
Showe, LC ;
Benoit, BM ;
Ubriani, R ;
Vittorio, CC ;
Junkins-Hopkins, JM ;
Wysocka, M ;
Rook, AH .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (04) :798-812
[7]   Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas [J].
Klemke, C-D ;
Fritzsching, B. ;
Franz, B. ;
Kleinmann, E. V. ;
Oberle, N. ;
Poenitz, N. ;
Sykora, J. ;
Banham, A. H. ;
Roncador, G. ;
Kuhn, A. ;
Goerdt, S. ;
Krammer, P. H. ;
Suri-Payer, E. .
LEUKEMIA, 2006, 20 (06) :1123-1129
[8]   Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma [J].
Mann, Bhupinder S. ;
Johnson, John R. ;
He, Kun ;
Sridhara, Rajeshwari ;
Abraham, Sophia ;
Booth, Brian P. ;
Verbois, Leigh ;
Morse, David E. ;
Jee, Josephine M. ;
Pope, Sarah ;
Harapanhalli, Ravi S. ;
Dagher, Ramzi ;
Farrell, Ann ;
Justice, Robert ;
Pazdur, Richard .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2318-2322
[9]   The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sezary syndrome [J].
McGinnis, KS ;
Ubriani, R ;
Newton, S ;
Junkins-Hopkins, JM ;
Vittorio, CC ;
Kim, EJ ;
Wysocka, M ;
Rook, AH .
ARCHIVES OF DERMATOLOGY, 2005, 141 (09) :1176-1178
[10]   Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma [J].
Olsen, Elise A. ;
Kim, Youn H. ;
Kuzel, Timothy M. ;
Pacheco, Theresa R. ;
Foss, Francine M. ;
Parker, Sareeta ;
Frankel, Stanley R. ;
Chen, Cong ;
Ricker, Justin L. ;
Arduino, Jean Marie ;
Duvic, Madeleine .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) :3109-3115
12